Stockreport

Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer [Yahoo! Finance...

ASTELLAS PHARMA UNSP/ADR  (ALPMY) 
NASDAQ:AMEX Investor Relations: astellas.com/jp/en/investors
PDF to target claudin 18.2, a biomarker positively expressed by 38% of patients with advanced gastric cancer Treatment with the claudin 18.2-targeted monoclonal antibody s [Read more]